How to buy Apellis Pharmaceuticals stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Apellis Pharmaceuticals stock

Own Apellis Pharmaceuticals stock in just a few minutes.

Apellis Pharmaceuticals, Inc is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 374 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Apellis Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Apellis Pharmaceuticals. Find the stock by name or ticker symbol: APLS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Apellis Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Apellis Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Apellis Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Apellis Pharmaceuticals share price

Use our graph to track the performance of APLS stocks over time.

Apellis Pharmaceuticals shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$25.49 - USD$58.47
50-day moving average USD$44.5391
200-day moving average USD$44.2489
Wall St. target priceUSD$64.14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.322

Buy Apellis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Apellis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Apellis Pharmaceuticals financials

Revenue TTM USD$250.6 million
Gross profit TTM USD$-74,325,000
Return on assets TTM -19.79%
Return on equity TTM -288.86%
Profit margin -137.59%
Book value $2.687
Market capitalisation USD$3.6 billion

TTM: trailing 12 months

Shorting Apellis Pharmaceuticals shares

There are currently 7.7 million Apellis Pharmaceuticals shares held short by investors – that's known as Apellis Pharmaceuticals's "short interest". This figure is 9.2% up from 7.0 million last month.

There are a few different ways that this level of interest in shorting Apellis Pharmaceuticals shares can be evaluated.

Apellis Pharmaceuticals's "short interest ratio" (SIR)

Apellis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Apellis Pharmaceuticals shares currently shorted divided by the average quantity of Apellis Pharmaceuticals shares traded daily (recently around 682199.82253771). Apellis Pharmaceuticals's SIR currently stands at 11.27. In other words for every 100,000 Apellis Pharmaceuticals shares traded daily on the market, roughly 11270 shares are currently held short.

However Apellis Pharmaceuticals's short interest can also be evaluated against the total number of Apellis Pharmaceuticals shares, or, against the total number of tradable Apellis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Apellis Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Apellis Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1422% of the tradable shares (for every 100,000 tradable Apellis Pharmaceuticals shares, roughly 142 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Apellis Pharmaceuticals.

Find out more about how you can short Apellis Pharmaceuticals stock.

Apellis Pharmaceuticals share dividends

We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.

Apellis Pharmaceuticals share price volatility

Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $25.49 up to $58.47. A popular way to gauge a stock's volatility is its "beta".

APLS.US volatility(beta: 1.46)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 1.4606. This would suggest that Apellis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Apellis Pharmaceuticals overview

Apellis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site